
HeartFlow Inc (HTFL) Stock Forecast & Price Target
HeartFlow Inc (HTFL) Analyst Ratings
Bulls say
HeartFlow is experiencing strong growth with a 41% increase in revenues and a 90bps improvement in gross margins. This trend is expected to continue, with the company projecting 4Q25 revenues to be consistent with 3Q25 and a forecast of $211MM for 2026, driven by strong utilization of their core FFR-CT business and the potential for additional revenue from their plaque analysis business. With a planned expansion into new markets and a conservative approach to revenue projections, the company's outlook remains positive for the future.
Bears say
HeartFlow is currently operating at a significant loss and is not projected to achieve profitability in the foreseeable future, making it a high-risk investment. The majority of the company's revenue is currently derived from one product, FFR CT Analysis, and the success of its second product, Plaque Analysis, is uncertain. The company's success is also reliant on the adoption of its technology by healthcare providers, and there is significant competition and uncertainty surrounding reimbursement and payment for the company's services. Additionally, HeartFlow is currently under investigation by the US Department of Justice, which could result in a financial settlement that could significantly impact the company's financials.
This aggregate rating is based on analysts' research of HeartFlow Inc and is not a guaranteed prediction by Public.com or investment advice.
HeartFlow Inc (HTFL) Analyst Forecast & Price Prediction
Start investing in HeartFlow Inc (HTFL)
Order type
Buy in
Order amount
Est. shares
0 shares